Special Awards In Pictures

Scientists say they have discovered a possible cure for all five known Ebola viruses. Antibodies that are used in the cure were discovered in the blood of a survivor. Kartik Chandran of the Albert Einstein College of Medicine helped discover the antibodies.

They are described online in the journal Cell. Chandran says studies of the antibody in non-human primates have shown positive results. He says he is optimistic that the antibodies can be used to protect and treat people, too.

A challenging history
The virus was given the name Ebola because the first recorded outbreak of the disease took place along the Ebola River in the Democratic Republic of Congo -- then known as Zaire -- in 1976.

Since then, there have been about 24 Ebola outbreaks in Africa, including one happening now in the DRC. Nine people have been infected and three people have died. The most recent Ebola epidemic took place from 2013 to 2016. It killed more than 11,000 people and infected 29,000 in Liberia, Guinea and Sierra Leone.

During that epidemic, researchers were studying an anti-Ebola drug called Zmapp. Doctors began using it even before the study was complete. Zmapp uses antibodies discovered in mice. They use the body’s natural immune system to fight infection. If the drug is given within five days after Ebola infection symptoms appear, it can cure the disease.

Promising results
But researcher Kartik Chandran says Zmapp is effective only against Ebola Zaire. It does not fight the other four known Ebola viruses. Chandran says the recently discovered human antibodies attack and destroy all five of the viruses. Researchers say the antibodies work by interfering with a process that the disease uses to infect and multiply inside cells. Chandran says scientists discovered the antibodies in just six months.

The drug company Mapp Pharmaceutical Incorporated is now testing the antibodies in monkeys that have been exposed to Ebola. Spokespeople for the company say the antibodies have so far been safe and effective.

Chandran says he hopes the antibodies can also be tested in people soon. And, he says, he hopes they can ultimately be used both as a treatment and as a vaccine to prevent people from getting Ebola in the first place.

Who we are

We dedicate time, energy, resources in the people who go out for the news.  We invest  in the  talents  and potentials of  the   professionals.  Basically, we focus on   capacity  building of our  people so that they can be prepared for the challenges ahead. We are the light for all. We  focus on the needs of our readers and bring to them new  level of  innovation that inspires them.

What we do

New Republic  tells the accurate stories as they come.  Investigate, capture moments and tell it as it comes. We bring to readers what  is news, what is informative and what is touching to add value to their business and  time. Importantly,  we do the job as our clients and readers would like to see. Moreover,  value  is added to whatever that we do to enhance productivity and longevity.

How we do it

We dedicate time, energy, resources in the people who go out for the news.  We invest  in the  talents  and potentials of  the   professionals. We look at the issues that make the news and bring  it to  our readers. The way of working is very unique and professional. Looking beyond the news is always our aim. Knowing what is behind the news is  crucial in all that we do.

When we do it

We do it just it  as it comes.  We get it out in a more  balanced and professional way as expected by the professionals  straight to  our readers. We do it at a time when  others do   not have it in mind. While others are searching, thinking, that is the time we release it to  our  readers. So, it comes at a privileged time where they will make  an  opinion on relevant issues.